ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
86,182.01
-0.66%
S&P 500
5,770.20
0.55%
Dow Jones
42,801.72
0.52%
US Dollar vs Yen
148.045
0.02%
Brent Oil
70.235
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) ニュース

MESO

Mesoblast (MESO)

Mesoblast Limited
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MESO
日付受信時刻ニュースソース見出しコード企業名
2025/03/0711 : 37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
2025/03/0708 : 54GlobeNewswire Inc.Mesoblast Added to S&P/ASX 200 INDEXNASDAQ:MESOMesoblast Limited
2025/02/2807 : 16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
2025/02/2707 : 30GlobeNewswire Inc.Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This QuarterNASDAQ:MESOMesoblast Limited
2025/02/2608 : 13GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
2025/02/2408 : 33GlobeNewswire Inc.Dr. Gregory George MD PhD Joins Mesoblast BoardNASDAQ:MESOMesoblast Limited
2025/02/1408 : 37GlobeNewswire Inc.Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation MeetingsNASDAQ:MESOMesoblast Limited
2025/02/1314 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MESOMesoblast Limited
2025/02/1306 : 04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MESOMesoblast Limited
2025/02/0705 : 05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MESOMesoblast Limited
2025/02/0605 : 59Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
2025/01/3109 : 11GlobeNewswire Inc.Ryoncil® Commercial Launch Update and Product PipelineNASDAQ:MESOMesoblast Limited
2025/01/3108 : 20GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024NASDAQ:MESOMesoblast Limited
2024/12/1909 : 08GlobeNewswire Inc.Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) TherapyNASDAQ:MESOMesoblast Limited
2024/12/1821 : 30GlobeNewswire Inc.Mesoblast to be Added to Nasdaq Biotechnology IndexNASDAQ:MESOMesoblast Limited
2024/12/1406 : 04Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:MESOMesoblast Limited
2024/12/1006 : 21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
2024/12/0508 : 32GlobeNewswire Inc.FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
2024/12/0308 : 20GlobeNewswire Inc.Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With InflammationNASDAQ:MESOMesoblast Limited
2024/11/1820 : 47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
2024/10/3108 : 11GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024NASDAQ:MESOMesoblast Limited
2024/10/1004 : 42Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MESOMesoblast Limited
2024/09/3009 : 55GlobeNewswire Inc.Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product LaunchNASDAQ:MESOMesoblast Limited
2024/08/2920 : 14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
2024/08/2908 : 27GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024NASDAQ:MESOMesoblast Limited
2024/08/2808 : 25GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
2024/07/3110 : 13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024NASDAQ:MESOMesoblast Limited
2024/07/2320 : 53GlobeNewswire Inc.FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
2024/07/2209 : 45GlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainNASDAQ:MESOMesoblast Limited
2024/07/0909 : 37GlobeNewswire Inc.Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

最近閲覧した銘柄

SPI
SP500
S&P 500
USOTC
BNPQY
BNP Paribas (QX)
CCOM
SILVER
SILVER
CCOM
US30
US 30
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
NYSE
BAC
Bank of America
COIN
ADAUSD
Cardano
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
NYSE
AXP
American Express
NYSE
XOM
Exxon Mobil
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す